News

Last year, the company also secured orphan designation for investigational drug candidate to treat glioblastoma. OS2966 selectively blocks CD29 (integrin b1 subunit), a dominant molecule modulating cell interactions

Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies

KX2-391 (KX01), a dual Src/pre-tubulin inhibitor, is a small molecule drug that has excellent skin penetration when formulated as a topical ointment. The pre-tubulin activity causes hyperproliferating cells

In the US, the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for brivaracetam as adjunctive therapy for the treatment of partial-onset

Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. The three Phase 1 studies were

The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The

Dexamethasone is being developed for administration as a one-time, bioresorbable intracanalicular plug for drug release to the ocular surface for up 30 days. A total of 40 patients

Nefecon is a new oral modified-release capsule of the corticosteroid, budesonide, being developed to treat patients with IgA nephropathy (IgAN) at risk of developing end-stage renal disease (ESRD),

Currently, the company has completed patient enrollment in a Phase III trial and it expects induction response rate data to be available in the second quarter of 2015.